Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jul;583(7815):290-295.
doi: 10.1038/s41586-020-2349-y. Epub 2020 May 18.

Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody

Dora Pinto #  1 , Young-Jun Park #  2 , Martina Beltramello #  1 , Alexandra C Walls #  2 , M Alejandra Tortorici  2   3 , Siro Bianchi  1 , Stefano Jaconi  1 , Katja Culap  1 , Fabrizia Zatta  1 , Anna De Marco  1 , Alessia Peter  1 , Barbara Guarino  1 , Roberto Spreafico  4 , Elisabetta Cameroni  1 , James Brett Case  5 , Rita E Chen  5   6 , Colin Havenar-Daughton  4 , Gyorgy Snell  4 , Amalio Telenti  4 , Herbert W Virgin  4 , Antonio Lanzavecchia  1   7 , Michael S Diamond  5   6   8 , Katja Fink  1 , David Veesler  9 , Davide Corti  10
Affiliations

Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody

Dora Pinto et al. Nature. 2020 Jul.

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a newly emerged coronavirus that is responsible for the current pandemic of coronavirus disease 2019 (COVID-19), which has resulted in more than 3.7 million infections and 260,000 deaths as of 6 May 20201,2. Vaccine and therapeutic discovery efforts are paramount to curb the pandemic spread of this zoonotic virus. The SARS-CoV-2 spike (S) glycoprotein promotes entry into host cells and is the main _target of neutralizing antibodies. Here we describe several monoclonal antibodies that _target the S glycoprotein of SARS-CoV-2, which we identified from memory B cells of an individual who was infected with severe acute respiratory syndrome coronavirus (SARS-CoV) in 2003. One antibody (named S309) potently neutralizes SARS-CoV-2 and SARS-CoV pseudoviruses as well as authentic SARS-CoV-2, by engaging the receptor-binding domain of the S glycoprotein. Using cryo-electron microscopy and binding assays, we show that S309 recognizes an epitope containing a glycan that is conserved within the Sarbecovirus subgenus, without competing with receptor attachment. Antibody cocktails that include S309 in combination with other antibodies that we identified further enhanced SARS-CoV-2 neutralization, and may limit the emergence of neutralization-escape mutants. These results pave the way for using S309 and antibody cocktails containing S309 for prophylaxis in individuals at a high risk of exposure or as a post-exposure therapy to limit or treat severe disease.

PubMed Disclaimer

Update of

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270–273 (2020). - DOI - PubMed - PMC
    1. Zhu, N. et al. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 382, 727–733 (2020). - PubMed - PMC
    1. Tortorici, M. A. & Veesler, D. Structural insights into coronavirus entry. Adv. Virus Res. 105, 93–116 (2019). - PubMed - PMC
    1. Walls, A. C. et al. Cryo-electron microscopy structure of a coronavirus spike glycoprotein trimer. Nature 531, 114–117 (2016). - PubMed - PMC
    1. Walls, A. C. et al. Tectonic conformational changes of a coronavirus spike glycoprotein promote membrane fusion. Proc. Natl Acad. Sci. USA 114, 11157–11162 (2017). - PubMed - PMC

Publication types

MeSH terms

LinkOut - more resources

  NODES
admin 1
twitter 2